Ocytocine and Cerebral Activation in Relation With Attachement

Study Overview
=================
Brief Summary
-----------------
The study aims to characterize the cerebral activation modifications related to nasal oxytocin administration during vizualisation of distress images in population of healthy people with different attachement styles.

Detailed Description
-----------------
Healthy adult male will be recruited. Their attachement style will be assessed through the Attachement scale interview (ASI). They will have 2 fMRI sessions, during which emotional images will be presented. One session will be preceded by a nasal administration of oxytocin and the other session will be preceded by a placebo nasal administration. The order of both administrations will be randomized.

Official Title
-----------------
A Cross Over Randomized Controlled Trial of the Effect of Nasal Ocytocine on Cerebral Activations in Relation With Attachement in the General Population

Conditions
-----------------
Attachement Style

Intervention / Treatment
-----------------
* Drug: nasal oxytocin or placebo
* Device: fMRI
* Behavioral: Attachement scale interview (ASI)
* Behavioral: psychometric scales


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: comprehension of french having signed the informed consent Exclusion Criteria: chronic disease (liver failure, kidney failure) and cardiovascular disease hypertensive treatment treatment wich increases QT current hospitalisation fMRI contraindication legal protection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: secure<br>healthy adult male with secure attachement | Drug: nasal oxytocin or placebo<br>* nasal administration of oxytocin or palcebo 45 min befor fMRI session<br>Device: fMRI<br>* FMRI during emotional image visualization<br>Behavioral: Attachement scale interview (ASI)<br>* this scale is used to determine the attachement style of each participant<br>Behavioral: psychometric scales<br>* self adminstrated questionnaires which asses the level of anxiety (Spielberger State-trait anxiety interview-STAI), depression (Beck depression inventory-BDI) and alexithymia (Toronta Alexuthymia scale-TAS 20)<br>|
| Experimental: avoidant<br>healthy adult male with avoidant attachement | Drug: nasal oxytocin or placebo<br>* nasal administration of oxytocin or palcebo 45 min befor fMRI session<br>Device: fMRI<br>* FMRI during emotional image visualization<br>Behavioral: Attachement scale interview (ASI)<br>* this scale is used to determine the attachement style of each participant<br>Behavioral: psychometric scales<br>* self adminstrated questionnaires which asses the level of anxiety (Spielberger State-trait anxiety interview-STAI), depression (Beck depression inventory-BDI) and alexithymia (Toronta Alexuthymia scale-TAS 20)<br>|
| Experimental: enmeshed/fearfull<br>healthy adult male with enmeshed/fearfull attachement | Drug: nasal oxytocin or placebo<br>* nasal administration of oxytocin or palcebo 45 min befor fMRI session<br>Device: fMRI<br>* FMRI during emotional image visualization<br>Behavioral: Attachement scale interview (ASI)<br>* this scale is used to determine the attachement style of each participant<br>Behavioral: psychometric scales<br>* self adminstrated questionnaires which asses the level of anxiety (Spielberger State-trait anxiety interview-STAI), depression (Beck depression inventory-BDI) and alexithymia (Toronta Alexuthymia scale-TAS 20)<br>|
| Experimental: dual style<br>healthy adult male with dual attachement style | Drug: nasal oxytocin or placebo<br>* nasal administration of oxytocin or palcebo 45 min befor fMRI session<br>Device: fMRI<br>* FMRI during emotional image visualization<br>Behavioral: Attachement scale interview (ASI)<br>* this scale is used to determine the attachement style of each participant<br>Behavioral: psychometric scales<br>* self adminstrated questionnaires which asses the level of anxiety (Spielberger State-trait anxiety interview-STAI), depression (Beck depression inventory-BDI) and alexithymia (Toronta Alexuthymia scale-TAS 20)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BOLD signal intensity | BOLD signal will be assessed in the brain regions associated with attachement: amygdala, medial prefrontal cortex and dorsolateral prefrontal cortex. Both conditions (placebo vs axytocin) will be compared in the four groups. BOLD signal will be assessed during the visualization of emotional pictures that ellicit distress, comfort or complicity or neural emotion. | 45 min after intranasal administration of oxytocin or placebo | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Attachement, Oxytocin, fMRI